-

CAPR 5-DAY DEADLINE: Capricor Investors Have Opportunity to Lead Class Action - HBSS

SAN FRANCISCO--(BUSINESS WIRE)--Hagens Berman notifies investors in Capricor Therapeutics, Inc. (NASDAQ: CAPR) of the September 28, 2026 lead plaintiff deadline in the pending securities class action.

“We're focused on investors’ losses and uncovering the full scope of how management characterized these trial endpoints and undisclosed modification,” said Reed Kathrein, the Hagens Berman partner leading the firm’s investigation.

Share

Submit Your CAPR Losses To HBSS

Key Details

Core Allegations

The lawsuit alleges that Capricor misrepresented clinical trial data and the regulatory pathway for its lead product candidate, Deramiocel, intended to treat Duchenne muscular dystrophy (DMD). Specifically, Defendants allegedly failed to disclose that they adopted changes to the pre-specified statistical analysis plan (SAP) without agreement from the FDA prior to resubmitting its Biologics License Application.

On July 27, 2026, the FDA published briefing documents that revealed that Capricor made unagreed-upon post-hoc modifications to its SAP. The FDA stated that the HOPE-3 study “did not meet its pre-specified primary and secondary efficacy endpoints showing no statistically significant difference between deramiocel and placebo at 12 months.” Capricor shares immediately crashed roughly 64%.

If you’d like more information and answers to frequently asked questions about the Capricor case and the firm’s investigation, read more »

Whistleblowers: Persons with non-public information regarding Capricor should consider their options to help in the investigation or take advantage of the SEC Whistleblower program. Under the new program, whistleblowers who provide original information may receive rewards totaling up to 30 percent of any successful recovery made by the SEC. For more information, call Reed Kathrein at 844-916-0895 or email CAPR@hbsslaw.com.

About Hagens Berman

Hagens Berman is a global plaintiffs’ rights complex litigation firm focusing on corporate accountability. The firm is home to a robust practice and represents investors as well as whistleblowers, workers, consumers and others in cases achieving real results for those harmed by corporate negligence and other wrongdoings. Hagens Berman’s team has secured more than $2.9 billion in this area of law. More about the firm and its successes can be found at hbsslaw.com. Follow the firm for updates and news at @ClassActionLaw.

Attorney Advertising. Prior results do not guarantee a similar outcome in any future case.

Contacts

Hagens Berman, Reed Kathrein, 715 Hearst Avenue, Suite 300, Berkeley, CA 94710, 844-916-0895, CAPR@hbsslaw.com

Hagens Berman

NASDAQ:CAPR

Release Summary
Hagens Berman is investigating claims in a class action complaint filed on behalf of investors in Capricor Therapeutics (CAPR) against the Company.
Release Versions
$Cashtags

Contacts

Hagens Berman, Reed Kathrein, 715 Hearst Avenue, Suite 300, Berkeley, CA 94710, 844-916-0895, CAPR@hbsslaw.com

Social Media Profiles
More News From Hagens Berman

PRCT ALERT: Hagens Berman Reminds PROCEPT BioRobotics (PRCT) Investors of the September 22, 2026 Lead Plaintiff Deadline

SAN FRANCISCO--(BUSINESS WIRE)--Hagens Berman is investigating claims in a class action complaint filed on behalf of investors in PROCEPT BioRobotics (PRCT) against the Company....

WIX ALERT: Hagens Berman Reminds Wix.com Ltd. (NASDAQ: WIX) Investors of September 22, 2026 Lead Plaintiff Deadline

SAN FRANCISCO--(BUSINESS WIRE)--Hagens Berman is investigating claims in a class action complaint filed on behalf of investors in Wix.com Ltd. (NASDAQ: WIX) against the Company....

CCOI 5-DAY DEADLINE ALERT: Hagens Berman Alerts CCOI Investors to September 21, 2026 Lead Plaintiff Deadline in Securities Class Action

SAN FRANCISCO--(BUSINESS WIRE)--Hagens Berman is investigating claims in a class action complaint filed on behalf of investors in Cogent Communications (CCOI) against the Company....
Back to Newsroom